Vaxcell-Bio Therapeutics Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	1,899	13.72	-	-	-
Revenue Growth	13737.28%	-	-	-	-
Cost of Revenue	1,537	10.44	16.43	19.37	5.39
Gross Profit	361.57	3.28	-16.43	-19.37	-5.39
Selling, General & Admin	8,002	6,171	5,793	3,811	2,714
Research & Development	6,040	4,919	2,075	1,810	1,350
Other Operating Expenses	23	20.67	16.62	6.57	0.44
Operating Expenses	15,443	11,510	8,196	5,885	4,250
Operating Income	-15,081	-11,507	-8,213	-5,904	-4,255
Interest Expense	-225.12	-43.66	-16.68	-26.9	-34.9
Interest & Investment Income	2,620	1,155	421.91	322.31	109.72
Currency Exchange Gain (Loss)	-1.51	-11.69	-	-	-
Other Non Operating Income (Expenses)	2,304	259.95	982.37	846.11	196.05
EBT Excluding Unusual Items	-10,384	-10,147	-6,825	-4,763	-3,984
Gain (Loss) on Sale of Investments	-182.7	-126.84	-	-	-
Gain (Loss) on Sale of Assets	-56.65	-	-0.05	-0.25	-
Pretax Income	-10,624	-10,274	-6,825	-4,763	-3,984
Net Income	-10,624	-10,274	-6,825	-4,763	-3,984
Net Income to Common	-10,624	-10,274	-6,825	-4,763	-3,984
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	23	20	15	15	7
Shares Outstanding (Diluted)	23	20	15	15	7
Shares Change	17.03%	28.80%	0.68%	122.02%	55.35%
EPS (Basic)	-463.00	-524.00	-448.34	-315.00	-585.00
EPS (Diluted)	-463.00	-524.00	-448.34	-315.00	-585.00
EPS Growth	-	-	-	-	-
Free Cash Flow	-12,824	-9,589	-6,212	-6,785	-3,330
Free Cash Flow Per Share	-558.88	-489.05	-408.07	-448.78	-488.95
Gross Margin	19.04%	23.90%	-	-	-
Operating Margin	-794.20%	-83851.26%	-	-	-
Profit Margin	-559.45%	-74865.84%	-	-	-
Free Cash Flow Margin	-675.31%	-69872.25%	-	-	-
EBITDA	-13,616	-11,107	-7,901	-5,647	-4,070
D&A For EBITDA	1,466	399.68	311.34	257.25	185.31
EBIT	-15,081	-11,507	-8,213	-5,904	-4,255
Advertising Expenses	409.6	77.55	38.41	2	19.76